These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8540311)

  • 1. Serum pepsinogen values as possible markers for evaluating the possibility of peptic ulcer recurrence under H2-blocker half-dose maintenance therapy.
    Matsushima M; Miki K; Ichinose M; Kakei N; Yahagi N; Kido M; Shimizu Y; Ishihama S; Tsukada S; Kurokawa K
    Adv Exp Med Biol; 1995; 362():131-7. PubMed ID: 8540311
    [No Abstract]   [Full Text] [Related]  

  • 2. Helicobacter pylori infection and serum pepsinogen I concentration in peptic ulcer patients: effect of bacterial eradication.
    Park SM; Park J; Chang SK; Yoo BC; Kim HJ
    Korean J Intern Med; 1996 Jan; 11(1):1-8. PubMed ID: 8882471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum pepsinogen I and recurrence of duodenal ulcer.
    Sumii K; Inbe A; Uemura N; Kimura M; Haruma K; Yoshihara M; Teshima H; Kajiyama G; Miyoshi A
    Scand J Gastroenterol; 1989 Dec; 24(10):1200-4. PubMed ID: 2574906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Peptic ulcer: current therapy].
    Pieragnoli E
    G Clin Med; 1987 Apr; 68(4):197-209. PubMed ID: 2886387
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum group I pepsinogens by radioimmunoassay in control subjects and patients with peptic ulcer.
    Samloff IM; Liebman WM; Panitch NM
    Gastroenterology; 1975 Jul; 69(1):83-90. PubMed ID: 1150038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The medical therapy of peptic ulcer. The state of the art].
    Perroni GB; De Matteis G; Pellizzeri F; Cassone A; Malara F
    Minerva Chir; 1992 Apr; 47(7):607-12. PubMed ID: 1350332
    [No Abstract]   [Full Text] [Related]  

  • 7. Pepsinogen Group I radioimmunoassay and total serum pepsinogen colorimetric determination: a comparative study in normal subjects and in peptic ulcer patients.
    Plebani M; Di Mario F; Vianello F; Giordano A; Masiero M; Lazzaretto M; Farini R; Ceriotti G; Naccarato R
    Clin Biochem; 1983 Feb; 16(1):20-2. PubMed ID: 6861334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of peptic ulcer. H2 receptor blockers].
    Domschke W
    Verh Dtsch Ges Inn Med; 1988; 94():272-5. PubMed ID: 2905101
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical, secretory, radiological and endoscopic evolution of patients with gastroduodenal ulcer treated with Ulcosilvanil, as compared with those treated with histamine H2 receptor antagonists].
    Contraşiu P; Calinici V
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1980; 32(4):359-63. PubMed ID: 6113650
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current aspects of course treatment and secondary prevention of peptic ulcer].
    Ryss ES
    Klin Med (Mosk); 1990 Apr; 68(4):134-42. PubMed ID: 1973467
    [No Abstract]   [Full Text] [Related]  

  • 11. [A clinico-endoscopic study on cicatrization of lesions and prevention of recurrences in patients with liver cirrhosis and peptic ulcer].
    Di Mario F; Gottardello L; Burra P; Salvagnini M; Dalrì L; Leandro G; Contento F; Torri A; Naccarato R
    G Clin Med; 1990 Apr; 71(4):259-62, 265-6. PubMed ID: 1973392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-ulcer drugs. Indications in adults. French Agency of the Safety of Health Products].
    Presse Med; 2000 Jan; 29(2):86-94. PubMed ID: 10682037
    [No Abstract]   [Full Text] [Related]  

  • 13. [New therapy of peptic ulcer].
    Harada T
    Nihon Naika Gakkai Zasshi; 1995 Mar; 84(3):386-9. PubMed ID: 7751774
    [No Abstract]   [Full Text] [Related]  

  • 14. Time, change and peptic ulcer disease in Rotherham, UK.
    Bardhan KD; Royston C
    Dig Liver Dis; 2008 Jul; 40(7):540-6. PubMed ID: 18407812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [H2 blockers in the treatment of bleeding gastroduodenal ulcers].
    Nikiforov PA; Bazarova MA; Nikitina SA; Osin VL; Shugurov VA
    Khirurgiia (Mosk); 2001; (10):49-50. PubMed ID: 11763821
    [No Abstract]   [Full Text] [Related]  

  • 16. A 35-year-old man with epigastric pain.
    Glickman R
    JAMA; 1995 Aug; 274(6):495-500. PubMed ID: 7629961
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan.
    Inoue M
    Drugs; 1988; 35 Suppl 3():114-9. PubMed ID: 2905239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future trends in the management of peptic ulcer disease.
    Misiewicz JJ
    Scand J Gastroenterol Suppl; 1988; 146():175-84. PubMed ID: 2906462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histamine H2-receptor antagonists as new anti-ulcer agents].
    Takemoto T
    Nihon Rinsho; 1984 Jan; 42(1):103-13. PubMed ID: 6143835
    [No Abstract]   [Full Text] [Related]  

  • 20. [Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
    Gorshkov VA
    Klin Med (Mosk); 2002; 80(9):66-70. PubMed ID: 12416232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.